Dimensional Fund Advisors LP Boosts Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Dimensional Fund Advisors LP increased its position in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 127.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 217,006 shares of the company's stock after purchasing an additional 121,598 shares during the period. Dimensional Fund Advisors LP owned 0.58% of Entrada Therapeutics worth $3,752,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Barclays PLC increased its position in Entrada Therapeutics by 13.9% during the fourth quarter. Barclays PLC now owns 51,365 shares of the company's stock worth $887,000 after purchasing an additional 6,255 shares during the last quarter. Renaissance Technologies LLC increased its position in Entrada Therapeutics by 77.2% during the fourth quarter. Renaissance Technologies LLC now owns 166,200 shares of the company's stock worth $2,874,000 after purchasing an additional 72,400 shares during the last quarter. Legal & General Group Plc increased its position in Entrada Therapeutics by 22.1% during the fourth quarter. Legal & General Group Plc now owns 19,899 shares of the company's stock worth $344,000 after purchasing an additional 3,601 shares during the last quarter. Invesco Ltd. acquired a new stake in Entrada Therapeutics during the fourth quarter worth about $199,000. Finally, Federated Hermes Inc. increased its position in Entrada Therapeutics by 3,104.3% during the fourth quarter. Federated Hermes Inc. now owns 99,814 shares of the company's stock worth $1,726,000 after purchasing an additional 96,699 shares during the last quarter. 86.39% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a "buy" rating and set a $20.00 price objective on shares of Entrada Therapeutics in a research report on Monday, March 31st.

Entrada Therapeutics Stock Down 1.0%

Shares of TRDA traded down $0.08 during trading on Monday, reaching $8.01. 121,121 shares of the company traded hands, compared to its average volume of 129,701. Entrada Therapeutics, Inc. has a twelve month low of $7.10 and a twelve month high of $21.79. The stock has a market cap of $304.00 million, a PE ratio of 5.04 and a beta of 0.04. The stock has a 50-day simple moving average of $8.87 and a 200-day simple moving average of $13.33.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.42) earnings per share for the quarter, beating analysts' consensus estimates of ($0.78) by $0.36. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. The business had revenue of $8.75 million during the quarter, compared to analysts' expectations of $10.98 million. On average, equities research analysts predict that Entrada Therapeutics, Inc. will post 1.12 EPS for the current year.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.